CT-AMT-130-02
32 evidence topics · 11 sources
Objective
Primary and secondary objectives in the EU Clinical Trials Register
Expanding exposure to both doses after the U.S. study
Dose selection for later development, March 2022
Location and study date
Sites in Poland, the United Kingdom, and Germany at first dosing, February 2022
Study sites and dates in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Site, Warsaw, Poland | “Instytut Psychiatrii i Neurologii” |
| Site, Warsaw, Poland | “Interventional Neuro Center” |
| Site, Cardiff, United Kingdom | “Cardiff University” |
| Site, London, United Kingdom | “National Hospital for Neurology & Neurosurgery” |
| Study start (actual) | “2021-10-07” |
| Primary completion (estimated) | “2029-03” |
| Study completion (estimated) | “2029-10-07” |
EU trial record after transition to the Clinical Trials Regulation
| Field | Record value |
|---|---|
| Protocol code | “CT-AMT-130-02” |
| Transition trial | “Yes” |
| Locations | “Poland” |
| Start of trial | “Start of trial 07/10/2021” |
| Current status in Poland | “Ongoing, recruitment ended” |
| Recruitment end in Poland | “15/10/2024” |
| Estimated global end date | “31/12/2029” |
Study design
Open-label Cohorts 1 and 2 and randomized Cohort 3 in the current registry record
Design fields in the current registry record
Non-randomized, open-label ascending-dose design: registry version 1, February 2022, superseded
Six-month post-treatment period followed by five years of follow-up
Eligibility criteria
Inclusion criteria in the EU Clinical Trials Register
Genetic and striatal volume criteria in the current registry record
Exclusion criteria: suicide attempt within 1 year
Same early manifest criteria as the U.S. study
Treatment
Doses by cohort in the current registry record
Investigational product concentration in the EU Clinical Trials Register
| Field | Register value |
|---|---|
| Concentration number | “2 x 10e13 gc/mL” |
All participants dosed with AMT-130
Study outcomes
Rationale for using safety measures as the primary endpoint
Integrated two-study program with staggered enrollment under one safety board
Primary outcomes at 6 months in the ClinicalTrials.gov record
Primary end points in the EU Clinical Trials Register
Secondary end points: vector DNA and miRNA expression in cerebrospinal fluid
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of 15 participants in two open-label cohorts, February 2022
Actual enrollment in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Enrollment (actual) | “14” |
Description of analysis sets
No evidence found.
Results
Participant disposition
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Suspected unexpected serious adverse reactions in two high-dose participants at one site, July 2022
Plan to resume dosing in the European study, November 2022
Safety notifications in the EU trial record
| Notification | Record value |
|---|---|
| Serious breach | “Serious Breach (0)” |
| Unexpected event | “Unexpected Event (0)” |
| Urgent safety measure | “Urgent Safety Measure (0)” |
| Temporary halt | “Temporary Halt (0)” |
Study limitations
Summary
- Open-label, uncontrolled design with inconsistent records: the EU Clinical Trials Register lists the trial as not controlled, not randomised, open, and not double blind. The ClinicalTrials.gov record describes open-label Cohorts 1 and 2 and randomization in Cohort 3 only, lists allocation as randomized and masking as none (open label), and gives an official title describing a randomized, double-blind study; version 1 (2022) listed a non-randomized, open-label design with an estimated enrollment of 15.
- Enrollment: 15 participants were planned (six low dose, nine high dose). The Form 10-K reports 13 participants enrolled and treated (six low dose, seven high dose), while the ClinicalTrials.gov record lists an actual enrollment of 14.
- Sites: the February 2022 release named sites in Poland, the United Kingdom, and Germany; the ClinicalTrials.gov record lists sites in Poland and the United Kingdom, and the CTIS record lists Poland.
- Results reporting: the pooled-analysis protocols pool data across the U.S. and EU studies, and the registered primary outcomes are safety and tolerability measures, including adverse events.
- Safety: suspected unexpected severe adverse reactions occurred in two high-dose participants treated at a single clinical site.